Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients – A review
Tacrolimus is a calcineurin inhibitor used to prevent rejection in allogenic solid organ transplant recipients, which is metabolized in the liver with cytochrome P450 isoforms 3A4 and 3A5 (CYP3A4, CYP3A5). In turn, proton pump inhibitors (PPIs), such as Omeprazole - a substrate and inhibitor of CYP2...
Main Authors: | Miłosz Miedziaszczyk, Ilona Idasiak-Piechocka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222300940X |
Similar Items
-
Assessment of omeprazole and famotidine effects on the pharmacokinetics of tacrolimus in patients following kidney transplant–randomized controlled trial
by: Miłosz Miedziaszczyk, et al.
Published: (2024-04-01) -
The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
by: Yi-Chang Zhao, et al.
Published: (2022-12-01) -
Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
by: Yoshiharu Suzuki, et al.
Published: (2021-08-01) -
Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food
by: Miłosz Miedziaszczyk, et al.
Published: (2022-10-01) -
Importance of Pharmacogenetics and Drug–Drug Interactions in a Kidney Transplanted Patient
by: Julia Concha, et al.
Published: (2023-07-01)